{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-096734","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.398393+00:00","generated_at":"2026-05-15T18:41:25.187210+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nurix Therapeutics ups ATM equity offering capacity to $413.65M","bullets":["Amendment No. 3 to Equity Distribution Agreement with Piper Sandler dated March 6, 2026.","Maximum aggregate gross offering price of common stock increased from $300M to $413.65M.","Shares offered at-the-market from time to time; prospectus supplement filed same day.","Proceeds not specified; prior ATM sales included in the increased limit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-096734","json":"https://secwatch.observer/filing/0001193125-26-096734.json","markdown":"https://secwatch.observer/filing/0001193125-26-096734.md","text":"https://secwatch.observer/filing/0001193125-26-096734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312526096734/0001193125-26-096734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312526096734/d32105d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:41:25.187210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}